39741-26-9

Usage

Uses

Used in Pharmaceutical Industry:
N-BENZOYL-L-ASPARTIC ACID-Beta-METHYL ESTER is used as a building block for the synthesis of peptides and peptide-based drugs, due to its ability to easily undergo chemical transformations and contribute to the development of various pharmaceuticals.
Used in Organic Synthesis:
N-BENZOYL-L-ASPARTIC ACID-Beta-METHYL ESTER is used as a reagent in organic synthesis, playing a significant role in the creation of complex organic molecules and compounds.
Used in Peptide Synthesis:
N-BENZOYL-L-ASPARTIC ACID-Beta-METHYL ESTER is used as a coupling reagent in peptide synthesis, facilitating the formation of peptide bonds between amino acids to create larger peptide structures.

Upstream product

• 16856-13-6 (+)-β-methyl-L-aspartate hydrochloride 
• 98-88-4 benzoyl chloride 
• 2177-62-0 β-methyl L-aspartate 

Downstream Products

• 100373-13-5 methyl 3-benzamido-4-oxovalerate 
• 54819-26-0 methyl 3-(benzoylamino)-4-oxovalerate 
• 107367-98-6 2-(5-Methyl-2-phenyl-4-oxazolyl)-acetic acid 
• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 
• 60272-64-2 2-phenyl-4-methoxycarbonylmethyl-5-oxo-4,5-dihydro-1,3-oxazole 
• 1562416-43-6 C₁₃H₁₅NO₅ 
• 86555-45-5 (2S)-N-benzoyl-L-aspartic acid dimethyl ester 
• 141200-66-0 5-<4-<<2-(5-methyl-2-phenyl-4-oxazolyl)ethyl>sulfonyl>benzyl>thiazolidine-2,4-dione 
• 132451-13-9 N-[4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenyl]-N-ethyl-2-(5-methyl-2-phenyl-oxazol-4-yl)-acetamide 
• 132451-26-4 5-[4-[N-Methyl-2-(5-methyl-2-phenyl-4-oxazolyl)acetamido]benzyl]thiazolidine-2,4-dione 
• 132451-20-8 5-<4-<2-(5-methyl-2-phenyl-4-oxazolyl)acetamido>benzyl>thiazolidine-2,4-dione 
• 132451-22-0 5-[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)-ethylthio]benzyl]thiazolidine-2,4-dione 
• 132451-21-9 5-<<4-<<2-(5-methyl-2-phenyl-4-oxazolyl)ethyl>thio>phenyl>methylene>thiazolidine-2,4-dione 
• 132451-34-4 4-[2-(5-methyl-2-phenyl-4-oxazolyl)-ethylthio]benzaldehyde 

Relevant academic research and scientific papers

Peptide-catalyzed conversion of racemic oxazol-5(4 H)-ones into enantiomerically enriched α-amino acid derivatives

We report the development and optimization of a tetrapeptide that catalyzes the methanolytic dynamic kinetic resolution of oxazol-5(4H)-ones (azlactones) with high levels of enantioinduction. Oxazolones possessing benzylic-type substituents were found to perform better than others, providing methyl ester products in 88:12 to 98:2 er. The mechanism of this peptide-catalyzed process was investigated through truncation studies and competition experiments. High-field NOESY analysis was performed to elucidate the solution-phase structure of the peptide, and we present a plausible model for catalysis.

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

In the course of further chemical modification of the novel antidiabetic pioglitazone (AD-4833, U-72, 107), a series of 5-[4-(2- or 4- azolylalkoxy)benzyl- or -benzylidene]-2,4-thiazolidinediones was prepared and evaluated for hypoglycemic and hypolipidemic activities in insulin-resistant, genetically obese, and diabetic KKA(y) mice. Replacement of the 2-pyridyl moiety of pioglitazone by a 2- or 4-oxazolyl or a 2- or 4-thiazolyl moiety greatly enhanced in vivo potency. The corresponding 5-benzylidene-type compounds, in which a methine was used as a linker between the benzene ring and the thiazolidinedione ring, also had potent biological activity. Among the compounds synthesized, 5-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxy]benzyl]-2,4-thiazolidinedione (18) exhibited the most potent activity, more than 100 times that of pioglitazone. The synthesis and structure-activity relationships for this novel series of derivatives are detailed.

Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents

A new series of thiazolidine-2,4-diones was obtained by replacing the ether function of englitazone with various functional groups, i.e., a ketone, alcohol, or olefin moiety.These compounds lower blood glucose levels in the genetically obese and insulin-r